Moonwalk pulls in $70M to take fat-targeting RNAi obesity candidate to clinic

Moonwalk Biosciences plans to shepherd its lead obesity asset into first-in-human trials in late 2027. In preclinical studies, MW101 has demonstrated weight loss and fat reduction while maintaining muscle mass.